18 research outputs found
Abstract 1518: Gene expression of trefoil proteins, gastrokines and mucins in Indian gastric cancer patients
No full textHigh expression of mesothelin in plasma and tissue is associated with poor prognosis and promotes invasion and metastasis in gastric cancer
No full textMesothelin (MSLN), a tumor-associated antigen, is upregulated in various malignancies, including gastric cancer (GC). In addition, MSLN is found in the blood-stream of affected individuals, where it is referred to as soluble MSLN-related protein (SMRP). This study aims to investigate the role of MSLN in GC and evaluate its potential as a plasma biomarker for diagnosis and prognosis. Toward that end, GC tissues were obtained, upon signed consent, from affected individuals undergoing surgery or endoscopy (n = 82). Quantitative RT-PCR and immunohistochemistry were performed to determine MSLN expression. Simultaneously, The Cancer Genome Atlas (TCGA) database was mined to evaluate global status of MSLN gene expression in gastric cancer. Next, in vitro cell-culture studies were conducted to evaluate MSLN-driven proliferation properties. Using ELISA, sera from 55 GC-affected individuals were tested for MSLN level. Additionally, plasma mesothelin levels were compared in 6 cases before and after surgery. Upregulated MSLN expression was found in GC tissues, compared to adjacent normal tissues (p < 0.001). Cell culture studies with a MSLN-overexpressing stable GC line showed increased cell proliferation and invasion with ectopic MSLN. Additionally, gene-set-enrichment-analysis (GSEA) revealed an association of MSLN with the genes involved in the epithelial-mesenchymal transition and G2/M checkpoint. GC-affected cases showed higher serum MSLN levels, compared to healthy controls, with rapid decrease post-surgery. We found that MSLN upregulation correlates with poor clinical outcome and promotes growth advantage to GC cells in vitro. With further experimental evidences, we propose that MSLN could potentially be used as a plasma biomarker for diagnosis of GC
Upregulation of ASPN in gastric tumors: Immunohistochemical staining of ASPN expression in gastric cancer tissue and the criteria for immunohistochemistry scoring.
No full textRepresentative IHC staining comparing ASPN expression in FFPE gastric tissues from GC patients. IHC staining is scored according to semi-quantitative immune-reactivity scoring. Score 0: no staining, score 1: weak staining, score 2: moderate staining, score 3: strong staining. Images of the gastric samples were taken at 100X and 400X magnification In, (A, B) (patient ID# OT63 Normal) Staining Intensity is 0; (C, D) (patient ID# CMCOT02 Tumor) staining intensity is 1; (E, F) (patient ID# 18S292 Tumor) represents the staining intensity of 2 and Fig. (G, H) (patient ID# OT 15 Tumor) represents the staining intensity of 3. Scale bars: 100X = 51μm and 400X = 20 μm. (S4 Table).</p
Materials and methods: Bioinformatics prediction and modeling of protein-protein interaction.
No full text(DOCX)</p
Expression fold changes of 58 genes with respect to adjacent normal samples that showed stage-wise upregulated in TCGA-STAD.
No full text(XLSX)</p
Expression of DCN: Gene expression analysis using quantitative real-time PCR suggests DCN is under expressed in gastric tumor tissue compare to adjacent normal in our OT cohort.
No full text(DOCX)</p
<i>ASPN</i> is upregulated in gastric tumors.
No full text(A) ASPN is upregulated in TCGA RNA Seq dataset (n = 407, mean ± SD, ***p ≤ 0.00,1 likelihood ratio test using DESeq2 method); (B, C) Gene expression analysis using quantitative real-time PCR suggests ASPN is highly expressed in gastric tumor tissue compare to adjacent normal in approx. 61.9% and 61.53% patients in OT Cohort and ENDO Cohort respectively. (n = 42 for OT Cohort and n = 35 for ENDO Cohort, mean ± SD, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, paired two tailed t test). (D) Heat map of 42 samples based on ASPN and DCN gene expression in our OT cohort. (E, F) ASPN and DCN expression was statistically associated with tumor stage: ASPN is overexpressing with increasing cancer stage whereas DCN showed an opposite result. (n = 398, mean ± SD, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, likelihood ratio test using DESeq2 method) (G, H) Expression of ASPN and DCN in Gastric tissues, adjacent normal and tumor samples, analysed using western blot assay: T1, T2, T3 are tumor tissues and N1, N2, and N3 are respective corresponding normal tissues.Data were quantified, normalized with β-actin and plotted (n = 3, mean ± SD, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, student’s t test).</p
